Literature DB >> 7513921

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.

J P Kleim1, R Bender, R Kirsch, C Meichsner, A Paessens, G Riess.   

Abstract

S-2720 and other members of the quinoline/quinoxaline class of HIV-1-specific nonnucleoside reverse transcriptase inhibitors (NNRTIs) select for a glycine to glutamate substitution at residue 190 (Gly 190 Glu) of the reverse transcriptase (RT), when drug-resistant viruses are generated in cell culture. This mutation has not been described to appear upon selection for resistant viral variants using derivatives of any other class of NNRTIs. Notably, the RNA-dependent DNA polymerase activity of the Gly 190 Glu mutant enzyme is drastically diminished with respect to the wild-type RT. We describe here the effects of other amino acid substitutions at position 190 of the RT that were introduced by using site-directed mutagenesis. Polymerase activities and sensitivities to inhibition by a number of NNRTIs were determined for the different RT mutants. In general, an inverse correlation was found between the enzymatic activity and increasing length of the side chain, whereas the size of the residue and the level of resistance to NNRTIs appeared to be positively related. Double mutants, which contain the Gly 190 Glu mutation together with substitutions that confer resistance to other RT inhibitors, were all shown to possess severely diminished polymerase activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513921     DOI: 10.1006/viro.1994.1233

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

3.  Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Authors:  H Pelemans; R Esnouf; A Dunkler; M A Parniak; A M Vandamme; A Karlsson; E De Clercq; J P Kleim; J Balzarini
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.

Authors:  Neil T Parkin; Soumi Gupta; Colombe Chappey; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 5.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

6.  A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer.

Authors:  P L Boyer; H Q Gao; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.

Authors:  R W Buckheit; K Watson; V Fliakas-Boltz; J Russell; T L Loftus; M C Osterling; J A Turpin; L A Pallansch; E L White; J W Lee; S H Lee; J W Oh; H S Kwon; S G Chung; E H Cho
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

8.  Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G Tachedjian; M French; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.

Authors:  R A Olmsted; D E Slade; L A Kopta; S M Poppe; T J Poel; S W Newport; K B Rank; C Biles; R A Morge; T J Dueweke; Y Yagi; D L Romero; R C Thomas; S K Sharma; W G Tarpley
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.

Authors:  V Miller; M P de Béthune; A Kober; M Stürmer; K Hertogs; R Pauwels; P Stoffels; S Staszewski
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.